US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Almirall SA

9.86

+0.0000

Volume:- -

Turnover:- -

Market Cap:2.10B

PE:-48.60

High:9.86

Open:9.86

Low:9.86

Close:9.86

Loading ...

Overview Company News Filings

Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025

Three Stocks With Estimated Undervaluation Worth Considering In February 2025

Simply Wall St.

Almirall SA (LBTSF) Q4 2024 Earnings Call Highlights: Surpassing Expectations with Strong ...

Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMRY\",,,,,undefined,":{"symbol":"ALMRY","market":"US","secType":"STK","nameCN":"Almirall SA","latestPrice":9.86,"timestamp":1744920000000,"preClose":9.86,"halted":0,"volume":0,"delay":15,"floatShares":76880097,"shares":213468718,"eps":-0.202881,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:00:00 EDT Delay","open":9.86,"high":9.86,"low":9.86,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.202881,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":9.86,"volumeRatio":0.7500000187500004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMRY\",,,,,undefined,":{"symbol":"ALMRY","floatShares":76880097,"roa":"1.32%","roe":"0.69%","lyrEps":-0.21588,"volumeRatio":0.7500000187500004,"shares":213468718,"dividePrice":0.216076,"high":9.86,"amplitude":0,"preClose":9.86,"low":9.86,"week52Low":9.28,"pbRate":"1.24","psRate":"1.87","week52High":10.62,"institutionHeld":0,"latestPrice":9.86,"eps":-0.202881,"divideRate":0.021914,"volume":0,"delay":15,"ttmEps":-0.202881,"open":9.86,"prevYearClose":9.9,"prevWeekClose":9.86,"prevMonthClose":9.86,"prevQuarterClose":9.86,"fiveDayClose":9.86,"twentyDayClose":9.86,"sixtyDayClose":9.9,"earningDate":1746979200000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517181848","title":"Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517181848","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517181848?lang=en_us&edition=fundamental","pubTime":"2025-03-06 15:06","pubTimestamp":1741244760,"startTime":"0","endTime":"0","summary":"CFO transition plan focusses on business continuity and the company’s strong growth trajectory as European leader in medical dermatology. Jon U. Garay Alonso has over 25 years of experience in business and finance in numerous leadership roles with increasing seniority in the pharma industry and other sectors. Mike McClellan will leave Almirall in September, after nearly six years as CFO, delivering a strong track and helping the company enter an era of sustained growth and profitability. BARCELONA, Spain, March 06, 2025----Almirall, S.A.  a global biopharmaceutical company based in Barcelona, today announced the appointment of Jon U. Garay Alonso as Chief Financial Officer and member of the company’s Management Board as of August 2025, succeeding Mike McClellan, who will leave the company in September 2025, after nearly six successful years as CFO.Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-announces-cfo-transition-plan-070600134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMRY","LBTSF","CNS","BK4135","BK4007"],"gpt_icon":0},{"id":"2514807486","title":"Three Stocks With Estimated Undervaluation Worth Considering In February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514807486","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514807486?lang=en_us&edition=fundamental","pubTime":"2025-02-26 12:02","pubTimestamp":1740542553,"startTime":"0","endTime":"0","summary":"In February 2025, global markets are experiencing a mix of geopolitical tensions and economic uncertainty, with U.S. stocks facing downward pressure due to concerns about consumer spending and potential new tariffs. Amid this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer resilience or growth potential despite broader market challenges.Overview: Almirall, S.A. is a biopharmaceutical company focused on the purchase, manufacture, storage, and sale of skin-health medicines across Europe, the Middle East, the United States, Asia, and Africa with a market cap of 2.08 billion.Operations: Almirall's revenue primarily stems from its activities in the biopharmaceutical sector, specifically through the production and distribution of skin-health medications across various regions including Europe, the Middle East, the United States, Asia, and Africa.Operations: The company's revenue segments include Hydro Energy , Hydro Extrusions , Hydr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-stocks-estimated-undervaluation-worth-040233830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4114","BK4007","MNSO","BK4505","ALMRY","LU1046422090.SGD","LBTSF","BK4585","BK4220","BK4588"],"gpt_icon":0},{"id":"2514305351","title":"Almirall SA (LBTSF) Q4 2024 Earnings Call Highlights: Surpassing Expectations with Strong ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514305351","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514305351?lang=en_us&edition=fundamental","pubTime":"2025-02-25 15:01","pubTimestamp":1740466860,"startTime":"0","endTime":"0","summary":"EBITDA: EUR192.6 million, surpassing the anticipated range of EUR175 million to EUR190 million.SG&A Expenses: EUR464.6 million, up 10% due to investments in EBGLYSS launch.R&D Investment: 12.6% of net sales, up 11.9% year-on-year.Ilumetri Sales: Over EUR200 million, with a new peak sales target of more than EUR300 million.EBGLYSS Sales: EUR33.2 million in its first year on the market.2025 Guidance: Net sales growth expected to accelerate to 10%-13%, with EBITDA projected between EUR220 million and EUR240 million.GuruFocus has detected 7 Warning Signs with LBTSF.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Almirall SA  surpassed its 2024 guidance, achieving double-digit net sales growth and an EBITDA of EUR192.6 million, exceeding the anticipated range.Almirall SA  has a strong R&D pipeline, with plans to initiate four proof of concept clinical studies in the next 15 months.Q: What are the expectations for EBGLYSS sales in 2025, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-sa-lbtsf-q4-2024-070100129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMRY","LBTSF"],"gpt_icon":0},{"id":"2513718969","title":"Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2513718969","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513718969?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:00","pubTimestamp":1740376800,"startTime":"0","endTime":"0","summary":"Almirall’s net sales growth in 2024 was 10.2% YoY  with EBITDA growth of 10.6% YoY  – surpassing guidance for the year with all key growth drivers delivering double digit growth.Company revenue growth continues to be driven by the strong performance of the European Dermatology business , specifically biologics.Ebglyss achieved 34% growth in Q4 compared to Q3, delivering a total of 33.2 MM sales in 2024, mainly in Germany. The product is now available in 11 markets across Europe and continues to receive very positive feedback from dermatologists.Ilumetri continued its very strong growth trajectory with 25.5% sales increase YoY, delivering sales of 208.8 MM – based on continued market expansion and taking a higher share from competition.Strong performance of Almiralls broad dermatology portfolio: Wynzora grew 53.3% YoY , and Klisyri grew 17.8% YoY . Sustained solid growth of the medical dermatology portfolio overall: 17.8% .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-2024-full-results-almirall-060000142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EC","CAGR","BK4159","ALMRY","LBTSF","BK4201","BK4007"],"gpt_icon":0},{"id":"2503551326","title":"Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2503551326","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503551326?lang=en_us&edition=fundamental","pubTime":"2025-01-14 14:00","pubTimestamp":1736834400,"startTime":"0","endTime":"0","summary":"Almirall's unique dedication to medical dermatology and innovation - combined with its commercial excellence - fuel an era of sustained double-digit growth  and profitability enabling the company to reach more patients with relevant and impactful products. Growth of Almirall’s psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in annual peak sales in biologics, driven by Ebglyss and Ilumetri. SAN FRANCISCO, January 14, 2025----Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales  and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its continued investment in R&D to innovate and advance scie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-jpmorgan-conference-entering-era-060000197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","LU1974910355.USD","LU2237443465.HKD","LU1917777945.USD","LU2430703251.USD","LU1496350502.SGD","LU0683600562.USD","LU1032466523.USD","LU0251132253.USD","IE00BKDWB100.SGD","LU2237443978.SGD","IE00BBT3K403.USD","LU1670627923.USD","LU0215105999.USD","IE00B3S45H60.SGD","LU2552382132.HKD","LU0211331839.USD","LU2505996681.GBP","LU0203347892.USD","LU2357305700.SGD","LU0976567544.SGD","IE00BLSP4452.SGD","LU0496365809.HKD","IE00BYXW3230.USD","LU2023250843.SGD","ALMRY","LU0211327993.USD","LU0170899867.USD","LU0267386448.USD","LU0234572021.USD","IE00B1XK9C88.USD","BK4207","JPM","LU1064131342.USD","LU2430703095.HKD","LU0323591593.USD","LU1894683348.USD","LU2552382215.SGD","LU0106831901.USD","LU0256863811.USD","LU1244550494.USD","LU0208291251.USD","LU1162221912.USD","IE00BLSP4239.USD","LU0971096721.USD","BK4566","LBTSF","LU0203345920.USD","LU0320765646.SGD","LU2552382058.USD","LU1244550221.USD"],"gpt_icon":0},{"id":"2489711506","title":"Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2489711506","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489711506?lang=en_us&edition=fundamental","pubTime":"2024-12-04 23:58","pubTimestamp":1733327880,"startTime":"0","endTime":"0","summary":"From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. . The Hive is aimed at advancing research in life sciences by a novel approach to collaboration - creating an open innovation hub designed to build close relationships between biotech companies, start-ups, academics, and Almiral","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZnnNut8PoTjtlvLzTcYR0Q--~B/aD0zMDI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ab0e6c8fd24134d0a7cca4234e4635e9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZnnNut8PoTjtlvLzTcYR0Q--~B/aD0zMDI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ab0e6c8fd24134d0a7cca4234e4635e9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-launches-hive-creating-novel-155800641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMRY","BK4131","HUBG","IE00B66KJ199.SGD","BK4179","IE00B7SZL793.SGD","LBTSF","IE0031619046.USD","BK4137","BK4007","IE00B19Z4B17.USD","NGS","HCSG"],"gpt_icon":0},{"id":"2483057903","title":"Eloxx Pharmaceuticals Announces Key Corporate Accomplishments","url":"https://stock-news.laohu8.com/highlight/detail?id=2483057903","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483057903?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome  presented in late-breaking presentation at American Society of Nephrology  Kidney Week. New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02. Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit. U.S. Food and Drug Administration  allows for continued dosing of subjects in Phase 1 trial of ZKN-013. New protein immunostaining and mass spectrometry analyses that were presented, confirmed the production of both collagen a4  and collagen a5  proteins in NMAS patients treated with ELX-02. Prior to treatment, collagen a4  and a5  were absent in the glomerulus in all three patients. Post treatment biopsy of the patient with the largest improvement in Filtration Slit Density showed a 34% increase in collagen a4  immunostaining intensity and presence of collagen a3/a4/a5  peptide ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kjX_a_h.bhQd.eOM7lsFxA--~B/aD0xODAwO3c9MjEwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/bcfc5fd94f5c621327303f3cfdec45a3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kjX_a_h.bhQd.eOM7lsFxA--~B/aD0xODAwO3c9MjEwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/bcfc5fd94f5c621327303f3cfdec45a3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eloxx-pharmaceuticals-announces-key-corporate-210500326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELOX","ALMRY","LBTSF","BK4007"],"gpt_icon":0},{"id":"2482278185","title":"Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2482278185","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482278185?lang=en_us&edition=fundamental","pubTime":"2024-11-11 15:12","pubTimestamp":1731309120,"startTime":"0","endTime":"0","summary":"Positive growth trajectory maintained with Net Sales increase of 7.9% to a total of 727.6 MM, EBITDA of 142.2 MM  driven by increased overall sales and strong performance of the biologics portfolio. Full year guidance for 2024 reiterated .The successful launch of Ebglyss in the first markets in Europe generated 20.4 MM in the initial nine months of 2024, representing a 34% sales increase quarter-on-quarter. The potential of lebrikizumab as a first line treatment for moderate to severe atopic dermatitis is demonstrated by the steadily increasing prescriptions in Germany, high product awareness, and strong feedback received from dermatologists and their patients - leading to significant gain of share in the dynamic market segment. The geographic expansion of lebrikizumab after the initial launch in Germany is progressing well with recent launches in Norway, UK, Spain, Denmark, and the Czech Republic. Ebglyss is on track to deliver against expectations for 2024 and anticipated peak sales ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7EKlOcVTMnYn371zVWw11Q--~B/aD00Njk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/646259f510cb7d25576896867f8daec9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7EKlOcVTMnYn371zVWw11Q--~B/aD00Njk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/646259f510cb7d25576896867f8daec9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-nine-month-2024-results-071200707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMRY","LBTSF","BK4007"],"gpt_icon":0},{"id":"2475519200","title":"Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2475519200","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475519200?lang=en_us&edition=fundamental","pubTime":"2024-10-15 14:30","pubTimestamp":1728973800,"startTime":"0","endTime":"0","summary":"Efinaconazole is a triazole antifungal compound indicated for the treatment of onychomycosis, a persistent and difficult to treat fungal infection of the nail. The completion of the decentralized regulatory procedure marks the final phase before European countries can grant national marketing authorizations. Efinaconazole is already available in Japan, the US, Canada, Korea, Hong Kong, and Macau and in 2021 Almirall obtained exclusive rights for the development and commercialization of efinaconazole in Europe from KAKEN PHARMACEUTICAL. BARCELONA, Spain, October 15, 2024----Almirall, S.A. , a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia.The successful completion of the decentralized procedure is the final step bef","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qv7sZUQJsrSuSBZo6Nv15A--~B/aD00Njk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e0f9b43bf89b5bf68da4c63fd334b9bc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qv7sZUQJsrSuSBZo6Nv15A--~B/aD00Njk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e0f9b43bf89b5bf68da4c63fd334b9bc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-announces-completion-decentralized-regulatory-063000539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ALMRY","LBTSF"],"gpt_icon":0},{"id":"2470237681","title":"New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2470237681","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470237681?lang=en_us&edition=fundamental","pubTime":"2024-09-25 18:45","pubTimestamp":1727261100,"startTime":"0","endTime":"0","summary":"Almirall will be celebrating 80 years at the EADV 2024 . Monthly lebrikizumab maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority  of ADvocate 1 and 2 responders. Nearly 87 percent of patients taking lebrikizumab did not require either high-potency topical corticosteroids or systemic treatments during the three-year period. The safety profile at three years was consistent with the previously published two-year results. \"Moderate-to-severe atopic dermatitis imposes a significant burden on patients, affecting their quality of life and overall wellbeing,\" said Prof. Dr. med. Diamant Thai, Director at the Institute and Comprehensive Centre for Inflammation Medicine, in Lübeck, Germany. \"These new three-year clinical data demonstrate the potential this biologic treatment has to provide sustained relief from this disease, offering long-term benefits to people living with this chronic and relapsing condition.\". 87 percent of these patients taking","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/41ryTmid8Vfom2jwKXOqOA--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/13fb43f0c55b8aa547865c3383c3800e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/41ryTmid8Vfom2jwKXOqOA--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/13fb43f0c55b8aa547865c3383c3800e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-show-almirall-ebglyss-lebrikizumab-104500187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LBTSF","ALMRY"],"gpt_icon":0},{"id":"2469677196","title":"Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2469677196","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469677196?lang=en_us&edition=fundamental","pubTime":"2024-09-23 18:09","pubTimestamp":1727086140,"startTime":"0","endTime":"0","summary":"New clinical data on Almirall’s biologics portfolio demonstrates further opportunities to positively impact patients and the medical community. New data to be presented on tildrakizumab for the treatment of moderate-to-severe psoriasis in adults from the POSITIVE study, the first clinical trial in dermatology to assess patients’ wellbeing as a primary endpoint. Lebrikizumab 3-year sustained moderate-to-severe atopic dermatitis control data will be presented as a late-breaker additional new data include response rates in absolute values and long-term data in patients that are either inadequately controlled or not eligible for cyclosporine treatment. Almirall’s broad presence at the 33rd EADV Congress – at the company’s 80th anniversary - highlights eight decades of dedication to innovation and delivering solutions to positively impact people’s health and lives. Almirall will host the symposium \"Advancing Psoriasis Management for Long-Term Patient Outcomes\", featuring experts such as Pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.YME1Raw_NxoKDdT.9nxBQ--~B/aD0yMTA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1ff868136d60f8a8601473a31f945f8e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.YME1Raw_NxoKDdT.9nxBQ--~B/aD0yMTA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1ff868136d60f8a8601473a31f945f8e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/almirall-present-data-biologics-psoriasis-100900247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMRY","LBTSF","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMRY\",params:#limit:5,,,undefined,":[{"date":"2024-07-22","symbol":"ALMRY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721635200000,"name":null,"time":"Pre-Market","dateTimestamp":1721620800000,"actualEps":null},{"date":"2024-06-03","symbol":"ALMRY","amount":0.19964,"announcedDate":"2024-05-24","type":"dividend","market":"US","newRecordDate":"2024-06-03","defaultRemindTime":1717421400000,"name":"Almirall SA","recordDate":"2024-06-25","payableDate":"2024-06-03","currency":"USD","dateTimestamp":1717387200000,"payDate":"2024-06-25"},{"date":"2024-05-13","symbol":"ALMRY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715587200000,"name":null,"time":"Pre-Market","dateTimestamp":1715572800000,"actualEps":null},{"date":"2022-11-10","symbol":"ALMRY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668070800000,"name":null,"time":"Pre-Market","dateTimestamp":1668056400000,"actualEps":null},{"date":"2022-07-25","symbol":"ALMRY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1658736000000,"name":null,"time":"Pre-Market","dateTimestamp":1658721600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMRY\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-03","recordDate":"2024-06-03","paymentDate":"2024-06-25","value":0.19964,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.8182,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8182,"analysts":11,"updateTime":1740542400000}}}